Galapagos NV’s service division Argenta has extended its contract drug discovery agreement with Genentech, a member of the Roche Group. The agreement covers several drug discovery programs that use Argenta’s computer-aided drug design (CADD), medicinal chemistry, in vitro biology and screening to discover new chemical entities against undisclosed drug targets defined by Genentech. The contract extension has a potential peak value of $33.7 million. The extended agreement also allows Genent...